Combining thrombolysis with the platelet glyco-protein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial (J Am Coll Cardiol, 1998)